To the Editor We are hopeful that induced pluripotent stem cells (iPSCs) will lead to powerful drug discovery platforms based on their ability to model disease at the cellular level and will serve as a reservoir of transplantable tissues for many diseases. Dr Mordwinkin and colleagues1 highlighted these aspects to assert that iPSC technology may reduce preclinical drug development times and more accurately predict efficacy and toxicity of novel or off-label therapeutic agents in human cardiomyocytes. However, iPSC-based technology is not the ideal platform for drug and toxicity screening or for the derivation of transplantable tissues.
Rao RC, Dlouhy BJ. Stem Cells and Cardiovascular Drug Development. JAMA. 2014;311(10):1070. doi:10.1001/jama.2014.631